Table 2.
Overview of mouse strains used in this study
| Mouse strain | Model | Plasma protein concentration (μg μl−1)a | Sourceb |
|---|---|---|---|
| C57BL/6 | Infectious diseases and diet-induced metabolic pathologies | 20.1 ± 2.06 | BioReclamationIVT |
| C57BL/6/CRL | 38.6 ± 1.94 | TCP (Charles River Laboratories, Wilmington, MA, USA) | |
| C57BL/6J | 42.3 ± 3.33 | TCP (Jackson Laboratory, Bar Harbor, ME, USA) | |
| 129S1/SvlmJ | Transgenic and knockout model development and stem cell line production | 42.0 ± 2.32 | TCP |
| NOD/SCID/J#1303 | Tumor biology and immunology | 37.8 ± 3.53 | TCP |
| BALB/cJ | Infectious diseases and immunology | 39.7 ± 2.30 | TCP |
| CD1 | General multipurpose model and mutant production | 45.4 ± 4.94 | TCP |
aMeans ± SD are shown
bC57BL/6/CRL and C57BL/6J mice were purchased from the respective vendors, and housed in the Toronto Centre for Phenogenomics (TCP; Toronto, ON, CA) prior to collection of plasma